{"id":49172,"date":"2022-10-05T11:01:40","date_gmt":"2022-10-05T09:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/"},"modified":"2022-10-05T11:01:40","modified_gmt":"2022-10-05T09:01:40","slug":"prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/","title":{"rendered":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies"},"content":{"rendered":"<div>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium Ltd (\u2018Prokarium\u2019 or the \u2018Company\u2019), a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent (Application No. 17\/344,065) protects the co-administration of Prokarium\u2019s Salmonella strains with cell therapies to enhance their therapeutic efficacy.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/5\/prokarium_logo_v4_Edit.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg\"><\/a><\/p>\n<p>\n\u201cThis newly issued patent demonstrates the innovative work our scientists are delivering every day to advance our proprietary platform\u201d, said Livija Deban, PhD, Chief Scientific Officer at Prokarium. \u201cThe majority of therapies in development do not address cancer-related immune dysfunction and our technology has the potential to restore a patient\u2019s immune fitness to drive deep and durable therapeutic responses.\u201d\n<\/p>\n<p>\nKristen Albright, PharmD, Chief Executive Officer of Prokarium, added, \u201cWe are very pleased to add to our growing IP estate. This patent brings to the forefront the innovative concept of live Salmonella as an oral immune training agent and strengthens the commercial partnering opportunities for the program, targeting the 80% of cancer patients that are unable to benefit from advanced immunotherapies today.\u201d\n<\/p>\n<p>\nSpecifically, the claims cover a method of simultaneously, separately, or sequentially administration of a live attenuated Salmonella bacterium delivered orally with an adoptive T cell therapy or an allogeneic or autologous CAR T-cell therapy to increase the therapeutic efficacy of the cell therapy. This patent highlights Prokarium as a leader in the microbial immunotherapy field.\n<\/p>\n<p>\n<b>About Prokarium<\/b>\n<\/p>\n<p>\nProkarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium\u2019s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<strong>For enquiries, please contact:<\/strong><br \/><strong>Investor Relations<\/strong><br \/>Lisa Stone<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;&#x74;o&#58;&#108;&#x69;&#x73;a&#46;&#115;&#x74;&#x6f;ne&#64;&#x70;&#x72;&#x6f;k&#97;&#x72;&#x69;&#x75;m&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#108;&#105;&#x73;&#x61;&#46;&#115;&#x74;&#x6f;&#110;&#101;&#x40;&#x70;&#114;&#111;&#x6b;&#x61;&#114;&#105;&#x75;&#x6d;&#46;&#99;&#x6f;&#x6d;<\/a><\/p>\n<p>For further information visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.prokarium.com&amp;esheet=52936315&amp;newsitemid=20221005005056&amp;lan=en-US&amp;anchor=www.prokarium.com&amp;index=1&amp;md5=8a851b6fa8b9d8efeb0025d64c7eec4e\" rel=\"nofollow noopener\" shape=\"rect\">www.prokarium.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium Ltd (\u2018Prokarium\u2019 or the \u2018Company\u2019), a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent (Application No. 17\/344,065) protects the co-administration of Prokarium\u2019s Salmonella strains with cell therapies to enhance their therapeutic efficacy. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49172","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium Ltd (\u2018Prokarium\u2019 or the \u2018Company\u2019), a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent (Application No. 17\/344,065) protects the co-administration of Prokarium\u2019s Salmonella strains with cell therapies to enhance their therapeutic efficacy. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T09:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies\",\"datePublished\":\"2022-10-05T09:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/\"},\"wordCount\":332,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005056\\\/en\\\/1591509\\\/21\\\/prokarium_logo_v4_Edit.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/\",\"name\":\"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005056\\\/en\\\/1591509\\\/21\\\/prokarium_logo_v4_Edit.jpg\",\"datePublished\":\"2022-10-05T09:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005056\\\/en\\\/1591509\\\/21\\\/prokarium_logo_v4_Edit.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221005005056\\\/en\\\/1591509\\\/21\\\/prokarium_logo_v4_Edit.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies - Pharma Trend","og_description":"LONDON&#8211;(BUSINESS WIRE)&#8211;Prokarium Ltd (\u2018Prokarium\u2019 or the \u2018Company\u2019), a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent (Application No. 17\/344,065) protects the co-administration of Prokarium\u2019s Salmonella strains with cell therapies to enhance their therapeutic efficacy. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-05T09:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies","datePublished":"2022-10-05T09:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/"},"wordCount":332,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/","url":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/","name":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg","datePublished":"2022-10-05T09:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221005005056\/en\/1591509\/21\/prokarium_logo_v4_Edit.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/prokarium-strengthens-patent-position-through-notice-of-allowance-of-us-patent-for-immunotherapy-prime-in-combination-with-cell-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49172"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49172\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}